Cellectar receives Nasdaq non-compliance notice; appoints Laurence Reilly as interim CMO

Cellectar Biosciences, Inc.

Received Nasdaq deficiency notice for bid price below $1 for 30 consecutive business days; has 180 days until May 2, 2022 to cure.
Appointed Laurence Reilly as interim CMO effective Nov 2; John Friend departs for personal reasons after transition.
Company asserts sufficient cash into 2H 2023; focused on iopofosine I-131 registrational trial in WM and other programs.
Dr. Reilly previously consulted for Cellectar; experience at Pfizer and Avillion; will oversee clinical development.

item 3.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

John Friend

Chief Medical Officer

CLRB · Cellectar Biosciences, Inc.

Effective: 2021-11-02
Successor: Laurence Reilly
Filed: November 2, 2021, 7:59 PM ET

Dr. Reilly succeeds John Friend, MD, who is stepping down but will stay on through mid-November to finalize the ongoing transition.

Appointed (interim)

Laurence Reilly

Interim Chief Medical Officer

CLRB · Cellectar Biosciences, Inc.

Effective: 2021-11-02
Filed: November 2, 2021, 7:59 PM ET

On November 2, 2021, the Company appointed Dr. Laurence Reilly as Interim Chief Medical Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

John Friend departed as Chief Medical Officer at Cellectar Biosciences, Inc..

Action: stepping down
Role: Chief Medical Officer

Exact text from the filing

Dr. Reilly succeeds John Friend, MD, who is stepping down but will stay on through mid-November to finalize the ongoing transition.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Laurence Reilly was appointed as Interim Chief Medical Officer at Cellectar Biosciences, Inc..

Action: appointed
Role: Interim Chief Medical Officer

Exact text from the filing

On November 2, 2021, the Company appointed Dr. Laurence Reilly as Interim Chief Medical Officer of the Company.

View on SEC.gov

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-132991

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.